Edgar Lomax Company’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.8M | Sell |
156,705
-14,625
| -9% | -$2.05M | 1.56% | 22 |
|
|
2025
Q4 | $21M | Sell |
171,330
-3,970
| -2% | -$482K | 1.6% | 25 |
|
|
2025
Q3 | $19.5M | Sell |
175,300
-52,355
| -23% | -$5.95M | 1.52% | 27 |
|
|
2025
Q2 | $25.2M | Sell |
227,655
-3,735
| -2% | -$397K | 1.6% | 27 |
|
|
2025
Q1 | $25.9M | Buy |
231,390
+105,800
| +84% | +$10.9M | 1.62% | 24 |
|
|
2024
Q4 | $11.6M | Sell |
125,590
-2,400
| -2% | -$216K | 0.75% | 43 |
|
|
2024
Q3 | $10.7M | Sell |
127,990
-1,990
| -2% | -$152K | 0.66% | 50 |
|
|
2024
Q2 | $8.92M | Sell |
129,980
-2,330
| -2% | -$155K | 0.58% | 51 |
|
|
2024
Q1 | $9.69M | Buy |
132,310
+32,411
| +32% | +$2.49M | 0.6% | 52 |
|
|
2023
Q4 | $8.09M | Sell |
99,899
-4,025
| -4% | -$313K | 0.53% | 43 |
|
|
2023
Q3 | $7.79M | Sell |
103,924
-1,745
| -2% | -$134K | 0.53% | 43 |
|
|
2023
Q2 | $8.14M | Sell |
105,669
-1,416
| -1% | -$113K | 0.54% | 43 |
|
|
2023
Q1 | $8.88M | Sell |
107,085
-115,415
| -52% | -$9.56M | 0.57% | 42 |
|
|
2022
Q4 | $19.1M | Sell |
222,500
-1,290
| -0.6% | -$102K | 1.16% | 34 |
|
|
2022
Q3 | $13.8M | Sell |
223,790
-2,545
| -1% | -$160K | 0.95% | 39 |
|
|
2022
Q2 | $14M | Buy |
226,335
+6,180
| +3% | +$383K | 0.88% | 38 |
|
|
2022
Q1 | $13.1M | Buy |
220,155
+60,335
| +38% | +$3.86M | 0.77% | 39 |
|
|
2021
Q4 | $11.6M | Sell |
159,820
-1,515
| -0.9% | -$104K | 0.69% | 44 |
|
|
2021
Q3 | $11.3M | Sell |
161,335
-2,950
| -2% | -$207K | 0.72% | 45 |
|
|
2021
Q2 | $11.3M | Sell |
164,285
-6,350
| -4% | -$424K | 0.7% | 45 |
|
|
2021
Q1 | $11M | Sell |
170,635
-4,480
| -3% | -$289K | 0.69% | 46 |
|
|
2020
Q4 | $10.2M | Sell |
175,115
-3,050
| -2% | -$184K | 0.69% | 42 |
|
|
2020
Q3 | $11.3M | Buy |
178,165
+7,200
| +4% | +$499K | 0.87% | 37 |
|
|
2020
Q2 | $13.2M | Buy |
170,965
+3,315
| +2% | +$254K | 1.05% | 30 |
|
|
2020
Q1 | $12.5M | Buy |
167,650
+23,800
| +17% | +$1.64M | 1.11% | 29 |
|
|
2019
Q4 | $9.35M | Sell |
143,850
-3,400
| -2% | -$221K | 0.6% | 47 |
|
|
2019
Q3 | $9.33M | Sell |
147,250
-1,500
| -1% | -$98.1K | 0.62% | 47 |
|
|
2019
Q2 | $10.1M | Sell |
148,750
-2,250
| -1% | -$148K | 0.68% | 45 |
|
|
2019
Q1 | $9.82M | Buy |
151,000
+21,300
| +16% | +$1.42M | 0.67% | 47 |
|
|
2018
Q4 | $8.11M | Sell |
129,700
-1,900
| -1% | -$133K | 0.62% | 45 |
|
|
2018
Q3 | $10.2M | Sell |
131,600
-4,500
| -3% | -$340K | 0.68% | 45 |
|
|
2018
Q2 | $9.64M | Buy |
136,100
+950
| +0.7% | +$67.1K | 0.68% | 46 |
|
|
2018
Q1 | $10.2M | Buy |
+135,150
| New | +$10.7M | 0.73% | 42 |
|
|
2017
Q1 | – | Sell |
-222,142
| Closed | -$15.9M | – | 65 |
|
|
2016
Q4 | $15.9M | Sell |
222,142
-20,183
| -8% | -$1.5M | 1.02% | 37 |
|
|
2016
Q3 | $19.2M | Sell |
242,325
-150
| -0.1% | -$12.2K | 1.19% | 32 |
|
|
2016
Q2 | $20.2M | Buy |
242,475
+12,325
| +5% | +$1.09M | 1.27% | 29 |
|
|
2016
Q1 | $21.1M | Buy |
230,150
+122,250
| +113% | +$11M | 1.45% | 24 |
|
|
2015
Q4 | $10.9M | Buy |
+107,900
| New | +$11.2M | 0.8% | 40 |
|
Other funds holding GILD
VCM
VPM
Edgar Lomax Company's GILD Position: Q1 2026 in Review
Edgar Lomax Company reduced its Gilead Sciences (GILD) stake by 8.5% in Q1 2026, selling an estimated $2.05M and leaving 156,705 shares worth $21.8M. The position accounts for 1.56% of the portfolio, ranked #22.
Edgar Lomax Company first reported a position in GILD in Q4 2015 and has held it in 38 quarters since. The position peaked at $25.9M in Q1 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Edgar Lomax Company held 156,705 shares of Gilead Sciences worth $21.8M as of Q1 2026.
- Edgar Lomax Company sold 14,625 Gilead Sciences shares in Q1 2026, an estimated $2.05M.
- Gilead Sciences made up 1.56% of Edgar Lomax Company's portfolio in Q1 2026, its #22 holding.
- Edgar Lomax Company first reported a position in Gilead Sciences in Q4 2015 and has held it in 38 quarters since.
- Edgar Lomax Company's Gilead Sciences position peaked at $25.9M in Q1 2025.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Edgar Lomax Company's 13F filing for Q1 2026, filed 12 May 2026.